Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 82 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Pectasides, Dimitrios  [Clear All Filters]
Journal Article
Koumarianou, A., Karayannopoulou G., Gourgioti G., Batistatou A., Bobos M., Efstratiou I., et al. (2015).  PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.. Cancer Chemother Pharmacol. 75(6), 1289-301.
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Skarlos, D. V., Timotheadou E., Galani E., Samantas E., Grimani I., Lianos E., et al. (2009).  Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic C. Oncology. 77(2), 107-12.
Papaxoinis, G., Kotoula V., Giannoulatou E., Koliou G-A., Karavasilis V., Lakis S., et al. (2018).  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.. Med Oncol. 35(7), 101.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Fountzilas, G., Psyrri A., Giannoulatou E., Tikas I., Manousou K., Rontogianni D., et al. (2018).  Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.. Int J Cancer. 142(1), 66-80.
Pectasides, E., Chatzidakis I., Kotoula V., Koliou G-A., Papadopoulou K., Giannoulatou E., et al. (2020).  Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.. Cancer Genomics Proteomics. 17(3), 277-290.
Levva, S., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Papadopoulou K., et al. (2017).  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.. Cancer Genomics Proteomics. 14(3), 181-195.
Economopoulou, P., Kotoula V., Koliou G-A., Papadopoulou K., Christodoulou C., Pentheroudakis G., et al. (2019).  Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.. Transl Oncol. 12(5), 739-748.
Fountzilas, E., Kotoula V., Pentheroudakis G., Manousou K., Polychronidou G., Vrettou E., et al. (2019).  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.. ESMO Open. 4(2), e000474.
Strimpakos, A., Pentheroudakis G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., et al. (2013).  The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.. Clin Colorectal Cancer. 12(4), 267-274.e2.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Fountzilas, E., Kotoula V., Tikas I., Manousou K., Papadopoulou K., Poulios C., et al. (2018).  Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.. Oncotarget. 9(86), 35623-35638.
Strati, T-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al. (2017).  Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.. Anticancer Res. 37(5), 2323-2334.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
Bafaloukos, D., Linardou H., Aravantinos G., Papadimitriou C., Bamias A., Fountzilas G., et al. (2010).  A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.. BMC Med. 8, 3.
Pectasides, D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., et al. (2015).  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 15, 384.
Pectasides, D., Dafni U., Bafaloukos D., Skarlos D., Polyzos A., Tsoutsos D., et al. (2009).  Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.. J Clin Oncol. 27(6), 939-44.
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.
Razis, E., Kalogeras K. T., Kotsantis I., Koliou G-A., Manousou K., Wirtz R., et al. (2020).  The Role of CXCL13 and CXCL9 in Early Breast Cancer.. Clin Breast Cancer. 20(1), e36-e53.
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές